Fresh2 Group ADR Aktie

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Fresh2 Group ADR Aktie had revenue of €1.63m and net profit of -€14m

(EUR)	2022	YoY
Revenue	1.63m	34.59%
Gross profit	1.13m	33.55%
Net profit	-14m	15.73%
EBITDA	-13.46m	10.60%

Fundamentals

Metric	Value
Market capitalization	€24.07m
Number of shares	6.27m
52-week high/low	€10.70 - €2.32
Dividends	No
Beta	1.56
P/E ratio	0.00
PEG ratio	0.00
P/B ratio	0.00
P/S ratio	1.15

Company profile

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.